Navigation Links
Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Date:9/14/2010

and Benefits 70

11 Global Renal Dialysis Equipment Market: Strategic Pipeline Assessment 71

11.1 Renal Dialysis Equipment: Pipeline Products Summary 71

11.2 Profiles of Promising Products under Clinical Development 72

11.2.1 HemoAccess Valve System (HVS) 72

11.2.2 AK 200 ULTRA S 72

11.2.3 AK 96 73

11.2.4 BetaSorb 73

11.2.5 OLpur H2H 74

11.2.6 XCR–6 74

11.2.7 Renal Expres 74

12 Global Renal Dialysis Equipment Market: M&A Landscape 76

12.1 Global Renal Dialysis Equipment Market: Deals Overview 76

12.2 Key Acquisitions 76

12.2.1 Asahi Kasei Kuraray Medical to Acquire Additional 53% Stake in Med-Tech 76

12.2.2 Asia Renal Care Acquires 20% Interest in Nephromed 77

12.2.3 Dialysis Corporation of America (DCA) Acquires St. Thomas More Dialysis Center 77

12.2.4 RA Group Holdings Acquires National Renal Alliance 77

13 Appendix 78

13.1 Definitions 78

13.1.1 Renal Dialysis Equipment 78

13.1.2 Continuous Renal Replacement Therapy Machines 78

13.1.3 Dialysis Accessories 78

13.1.4 Hemodialysis Machines 78

13.1.5 Peritoneal Dialysis Solutions 79

13.2 Acronyms 79

13.3 Research Methodology 80

13.4 Secondary Research 81

13.5 Primary Research 81

13.6 Models 82

13.7 Forecasts 82

13.8 Expert Panels 82

13.9 GlobalData Consulting 82

13.10 Contact Us 83

13.11 Disclaimer 83

1.1 List of TablesTable 1: Classification of Acute Renal Failure by RIFLE system 8

Table 2: Causes Of Renal Failure in the US, 2007 9

Table 3: Causes of Renal Failure in Europe, 2007 10

Table 4: Renal Failure Prevalence, '000s, US, 2008 12

Table 5: Renal Failure Prevalence, Europe, '000s 2007 13

Table 6: Renal Dialysis Equipment Market, Global, Revenue ($m), 2002–2009 16

Table 7: Renal Dialysis Equipment Market, Global,
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
2. Reportlinker Adds Cardiovascular Surgery Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
3. Reportlinker Adds Respiratory Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
4. Reportlinker Adds Autistic Disorder - Pipeline Assessment and Market Forecasts to 2017
5. Reportlinker Adds Pharmaceutical Preparation Manufacturing Industry in the U.S. and Its International Trade [Q3 2010 Edition]
6. Reportlinker Adds US Enzymes Market
7. Reportlinker Adds Trends and Strategies in Pharmaceutical and Medical Device Branding
8. Reportlinker Adds Clinical Trials in China
9. Reportlinker Adds The Top 10 Orthopedic Device Companies: Financial performance, research activities, and growth strategies
10. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
11. Reportlinker Adds Drug Delivery in Central Nervous System Diseases - technologies,markets and companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Intarcia Therapeutics, Inc. today announced successful top-line results ... for ITCA 650 (exenatide, delivered continuously once or twice ... trial, FREEDOM-1, was a placebo-controlled, double-blind phase 3 clinical ... 650 in patients with type 2 diabetes against placebo. ... to placebo for both 40 mcg and 60 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 ... now available. Interested parties can learn about ... Cardinal Health is supporting the health care ... http://cardinalhealth.com/annualreport . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... summary financials and the chief executive officer,s ...
(Date:10/1/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a ... used to develop and produce enzymes and other ... industrial enzymes industries, today announced the receipt of ... commercial scale production of Abengoa,s proprietary cellulase enzymes, ... Abengoa,s license agreement with Dyadic. ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... the worldwide leader in handheld x-ray technologies, has been ... Edison Best New Product Awards™. The winners were announced ... ballroom in New York City.  The NOMAD® Handheld X-ray ... Medical Handheld or Miniaturized Devices Segment. ...
... PRA International, a leading Clinical Research Organization, announces that ... will speak at the World Drug Safety Congress being held ... host an exhibit at booth #2. Dr. ... first breakout stream, "Operational Safety," on 13 April at 1:50 ...
Cached Medicine Technology:NOMAD by Aribex Receives Edison Best New Product Award 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/1/2014)... researchers from the University of Adelaide have developed a ... of a good outcome from treatment - from their ... on a range of factors, including clinical symptoms, cognitive ... in the patient,s blood. , Speaking in the lead ... University,s Head of Psychiatry , Professor Bernhard ...
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog ... couples. , Senior citizens can purchase a joint ... loved ones. A joint policy is cheaper, but will ... , Life insurance can be used to cover ... be purchased online, as the application process is simple ...
(Date:10/1/2014)... 01, 2014 Phoseon Technology, the pioneer ... to expand the business worldwide. This rapid growth includes ... capacity for manufacturing efforts. The company has experienced average ... years and expects this growth to continue in the ... gains worldwide adoption. , “We are very pleased ...
Breaking Medicine News(10 mins):Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... , , TAMPA, Fla. ... Solutions, today announced the appointment of Michael Unhjem as a member of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090709/FL43703LOGO ) , ... of Blue Cross Blue Shield (BCBS) of North Dakota, was unanimously elected ...
... SEATTLE, July 20 Group Health Cooperative medical centers received ... the Puget Sound Health Alliance Community Checkup . Group ... nine medical groups in the Puget Sound region that were rated on ... regional average" scores. , , "We support ...
... , MINNEAPOLIS, July 20 ... into a business relationship with Cardiocom(R) to provide advanced home ... Experts in Telehealth(SM), is a world class developer, manufacturer and ... , Cardiocom,s telehealth system provides an interactive ...
... 20 N y comed tod a y announced t h e su b mission of a N e ... n d Drug Administr a tion ( F DA) for ... oral treatme n t for patie n t s ... i ssion is ba s e d on enc ou raging result s fro m ...
... , , ... DIEGO, July 20 Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX ) today ... its investigational drug for the treatment of obesity, met their co-primary endpoints. ... O besity R esearch, or COR, program of more ...
... , , ... -- Allscripts (Nasdaq: MDRX ) announced today ... Human Resources. Ms. Adams brings to the position more than 20 ... high tech industry, most recently as Vice President of Human Resources ...
Cached Medicine News:Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 2Health News:Michael Unhjem Appointed to Board of Directors for Health Integrated 3Health News:Group Health Cooperative Scored Above Regional Average in 11 of 15 Quality Measures 2Health News:Silas Home Care Selects Cardiocom Telehealth Technology 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 2Health News:Nycomed Announces FDA Filing for Daxas(R) in COPD 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 2Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 3Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 4Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 5Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 6Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 7Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 8Health News:-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments- 9Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 2Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 3Health News:Diane Adams Joins Allscripts as Executive Vice President, Human Resources 4
3 mm disposable bevel blades. Malleable shafts. Blades packaged 6 per package....
Straight 8 mm downcutting Royce blade. Can be placed in closed handle for protection. Rigid handle when folded and locked. Straight 8 mm downcutting blades. Handle length folded 109 mm, 4.3 inches....
2 mm diameter blade. Angled 60 degrees. Sharp. Round handle....
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
Medicine Products: